Does Rallies show Form 4 insider transactions for PACB?

Yes. Rallies tracks PACB insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is PACB research on Rallies investment advice?

No. Rallies provides research, data, and educational context for PACB. It does not provide personalized investment advice.

PACB (Pacific Biosciences of California, Inc.) Stock Analysis - Insider Trades

Pacific Biosciences of California, Inc. (PACB) is a publicly traded Healthcare sector company. As of May 21, 2026, PACB trades at $1.22 with a market cap of $357.19M and a P/E ratio of -2.71. PACB moved +3.91% today. Year to date, PACB is -39.90%; over the trailing twelve months it is +16.67%. Its 52-week range spans $0.85 to $2.73. Analyst consensus is neutral with an average price target of $2.38. Rallies surfaces PACB's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading PACB stock inside the company?

Recent PACB insider activity includes Gibson James R II sold 88.19K, HENRY CHRISTIAN O sold 12.50K, Van Oene Mark sold 6.50K, Farmer Michele sold 2.98K, and Van Oene Mark sold 55.11K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

PACB Key Metrics

Key financial metrics for PACB
Metric	Value
Price	$1.22
Market Cap	$357.19M
P/E Ratio	-2.71
EPS	$-0.43
Dividend Yield	0.00%
52-Week High	$2.73
52-Week Low	$0.85
Volume	9.14K
Avg Volume	0
Revenue (TTM)	$160.03M
Net Income	$-128.58M
Gross Margin	37.49%

Recent PACB Insider Trades

Gibson James R II sold 88.19K (~$120.81K) on Apr 1, 2026.
HENRY CHRISTIAN O sold 12.50K (~$18.92K) on Mar 3, 2026.
Van Oene Mark sold 6.50K (~$9.85K) on Mar 3, 2026.
Farmer Michele sold 2.98K (~$4.51K) on Mar 3, 2026.
Van Oene Mark sold 55.11K (~$89.77K) on Feb 18, 2026.

Latest PACB News

PacBio HiFi Sequencing Identifies Genetic Causes in ~10% of Subfertile Couples — May 11, 2026
Pacific Biosciences Posts $0.12 Q1 Loss, Revenues Miss Estimates — May 7, 2026
PacBio Integrates Lucid Genomics for Streamlined HiFi Sequencing Analysis — Apr 21, 2026
PacBio, Covaris Launch FFPE Workflow Yielding 100M HiFi Reads and 5,000bp Fragments — Apr 15, 2026
PacBio Powers Trillion Gene Atlas with HiFi Sequencing for 100,000 Samples — Mar 18, 2026

PACB Analyst Consensus

4 analysts cover PACB: 0 strong buy, 2 buy, 1 hold, 1 sell, 0 strong sell. Consensus rating is neutral. Average price target: $2.38.

Common questions about PACB

Who is trading PACB stock inside the company?: Recent PACB insider activity includes Gibson James R II sold 88.19K, HENRY CHRISTIAN O sold 12.50K, Van Oene Mark sold 6.50K, Farmer Michele sold 2.98K, and Van Oene Mark sold 55.11K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for PACB?: Yes. Rallies tracks PACB insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is PACB research on Rallies investment advice?: No. Rallies provides research, data, and educational context for PACB. It does not provide personalized investment advice.